Moutai’s dividend yield has surpassed Agricultural Bank of China’s for the first time, boosting the premium liquor maker’s appeal to income investors despite slowing growth https://t.co/h8rusXqesq ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a ...

CHICAGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (NASDAQ: MRCC) today announced its financial results for the second quarter ended June 30, 2025. In a separate joint release issued on August 7, 2025, MRCC and Horizon Technology Finance Corporation ("HRZN") announced that they have entered into a definitive merger agreement (the "Merger Agreement"), under which MRCC would merge with and into HRZN (the "Merger"), subject to the receipt of certain shareholder approvals and the satisfaction ...

Core Insights - The article emphasizes the importance of sustainability in high-yield dividend-paying companies to avoid sudden dividend reductions [1] - It highlights the strategy of constructing investment portfolios that focus on both Dividend Yield and Dividend Growth to enhance annual dividend income [1] - The approach includes diversification across various sectors and industries to minimize portfolio volatility and risk [1] Group 1: Investment Strategy - The investment strategy prioritizes companies with significant competitive advantages and strong financials to ensure attractive returns [1] - A blend of ETFs and individual companies is suggested to achieve broad diversification and risk reduction [1] - The selection process for high dividend yield and growth companies is meticulously curated, focusing on total return rather than dividends alone [1] Group 2: Risk Management - Incorporating companies with a low Beta Factor is recommended to further reduce the overall risk level of the investment portfolio [1] - The diversification strategy aims to mitigate risk and enhance the stability of income sources [1]

Core Viewpoint - Pfizer's stock has recently rebounded due to strong Q2 earnings, indicating potential for future growth as the company navigates post-pandemic challenges [1][2] Financial Performance - Pfizer's dividend yield has reached 7.3%, attracting investors despite the company's struggles post-COVID-19 [4] - The company has maintained its dividend for 15 consecutive years, with the current dividend at $1.72 per share, which is well below the midpoint of management's 2025 adjusted EPS guidance of $3 per share [5][6] Growth Prospects - Pfizer has raised its 2025 adjusted earnings guidance from $2.80-$3.00 to $2.90-$3.10 per share, focusing on growth in oncology and specialty drugs, which are less likely to face pricing pressures [8] - Specialty drug sales have increased by 6% year over year, while oncology sales have risen by 9% through six months of 2025, contributing approximately $16.5 billion to sales [9][10] Market Sentiment - Analysts project Pfizer's earnings to grow at an annualized rate of 9% over the next three to five years, despite current market concerns regarding tariffs and political pressures [11] - The stock is currently trading at just 8 times the midpoint of its 2025 earnings guidance, suggesting a significant undervaluation given its growth potential [13] Investment Appeal - Pfizer presents a compelling investment opportunity for income-focused investors due to its high dividend yield, potential for high-single-digit growth, and a valuation that could increase with improved market sentiment [14][15]

Celanese Corporation CE will release earnings results for the second quarter after the closing bell on Monday, Aug. 11.Analysts expect the Irving, Texas-based company to report quarterly earnings at $1.40 per share. That’s down from $2.38 per share in the year-ago period. Celanese is projected to report quarterly revenue at $2.49 billion, compared to $2.65 billion a year earlier, according to data from Benzinga Pro.With the recent buzz around Celanese, some investors may be eyeing potential gains from the c ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.Below are the ratings of the most accurate analysts for three high-yield ...

Group 1 - Zepp Health Corporation has experienced revenue drops and negative net income but shows potential for future growth following its transition to a new independent brand [1] - The stock is considered a strong buy option based on the current analysis [1] - The analysis emphasizes a bottom-up approach focusing on operational fundamentals, execution history, and sustainable growth drivers [1] Group 2 - The investment philosophy combines income and value investing strategies, highlighting the importance of dividend yield as a risk mitigation criterion [1] - The analyst prioritizes companies with smaller capitalization and low institutional coverage, identifying greater potential for asymmetries and alpha generation [1] - The analysis includes a triangulation approach involving valuation by multiples, discounted cash flow (DCF), and dividend yield [1]

Earnings Report - Gilead Sciences, Inc. is set to release its second-quarter earnings results on August 7, with analysts expecting earnings of $1.96 per share, a decrease from $2.01 per share in the same period last year [1] - The projected quarterly revenue is $6.96 billion, slightly up from $6.95 billion a year earlier [1] Analyst Upgrade - Needham analyst Joseph Stringer upgraded Gilead Sciences from Hold to Buy, setting a price target of $133 [2] - The company currently offers an annual dividend yield of 2.87%, translating to a quarterly dividend of 79 cents per share, or $3.16 annually [2] Dividend Strategy - To achieve a monthly income of $500 from dividends, an investment of approximately $209,422 or around 1,899 shares is required [2] - For a more modest monthly income of $100, an investment of $41,906 or around 380 shares is necessary [2] Dividend Yield Calculation - The dividend yield is calculated by dividing the annual dividend payment by the stock's current price, which can fluctuate based on stock price changes [3] - Changes in dividend payments also affect the yield; an increase in dividends raises the yield if the stock price remains constant, while a decrease lowers it [4] Stock Performance - Gilead Sciences shares fell by 1.9%, closing at $110.28 on Wednesday [4]

The company started its phase of high cash flow generation from investments of previous years and now it will leverage itself and establish as a mature company, surpassing investor expectations. Despite having a debt, the company has its focus onI am a financial analyst currently studying for the Chartered Financial Analyst (CFA) - I have learned to invest mostly by Mark Meldrum courses. My analyses follow an approach based on the triangulation between valuation by multiples, discounted cash flow (DCF) and ...